% 0期刊文章% p . j .西达% m . j .表亲% A . Otte % T葛瑞斯%墨菲一个T·k·R·钱伯斯% % T中部与神经性疼痛与脊髓损伤2006% % B安慰剂对照试验% D R wnl.0000244422.45278 10.1212/01.。ff % J首页神经病学% P 1792 - 1800 X % V 67% N 10%目的:评估与中部的神经性疼痛与脊髓损伤有关。方法:12周,多中心研究的患者随机要么flexible-dose普瑞巴林150到600毫克/天(n = 70)或安慰剂(n = 67),进行报价。病人被允许保留在现有的稳定的疼痛治疗。主要疗效变量是端点代表痛苦得分,来自病人的最后7天每天疼痛日记。关键二次端点包括疼痛应答率,SF-MPQ,睡眠干扰,情绪,和病人全球的变化。结果:平均基线与组疼痛评分是6.54和6.73在安慰剂组。意味着端点与组的疼痛评分较低比安慰剂组(4.62)(6.27;p < 0.001),疗效观察早在第一周期间和维护。普瑞巴林的平均剂量后三星期的稳定阶段是460毫克/天。普瑞巴林显著优于安慰剂在SF-MPQ端点的评估。 The ≥30% and ≥50% pain responder rates were higher with pregabalin than placebo (p < 0.05). Pregabalin was associated with improvements in disturbed sleep (p < 0.001) and anxiety (p < 0.05), and more patients reported global improvement at endpoint in the pregabalin group (p < 0.001). Mild or moderate, typically transient, somnolence and dizziness were the most common adverse events. Conclusions: Pregabalin 150 to 600 mg/day was effective in relieving central neuropathic pain, improving sleep, anxiety, and overall patient status in patients with spinal cord injury. %U //www.ez-admanager.com/content/neurology/67/10/1792.full.pdf